Fibrino
Generic Name
Human Fibrinogen Concentrate
Manufacturer
Generic Pharma Co.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| fibrino 500 mg injection | ৳ 50.00 | N/A |
Description
Overview of the medicine
Fibrino 500 mg Injection is a human plasma-derived fibrinogen concentrate used for the treatment of bleeding episodes and perioperative prophylaxis in patients with congenital or acquired fibrinogen deficiency.
Uses & Indications
Dosage
Adults
Dosage depends on the severity of bleeding, fibrinogen levels, and clinical condition. Typically, an initial dose of 70 mg/kg body weight is given, then adjusted based on monitoring.
Elderly
No specific dosage adjustment required, but use with caution and monitor for signs of fluid overload or thrombotic events due to increased risk factors in this population.
Renal_impairment
Use with caution due to potential for fluid overload. Monitor fluid balance and fibrinogen levels closely. No specific dose adjustment guidelines are available.
How to Take
Administered intravenously after reconstitution with the provided solvent for injection. The solution should be inspected visually for particulate matter and discoloration prior to administration. Infuse slowly.
Mechanism of Action
Fibrinogen is a soluble plasma glycoprotein that is converted by thrombin into insoluble fibrin during blood coagulation. This fibrin then polymerizes to form a stable clot, which is essential for hemostasis. The administration of Fibrino increases plasma fibrinogen levels, thereby restoring or improving the patient's hemostatic function.
Pharmacokinetics
Onset
Immediate upon intravenous administration.
Excretion
Metabolites are primarily excreted via the renal pathway.
Half life
Approximately 79 ± 16 hours (about 3-4 days).
Absorption
Administered intravenously, resulting in 100% bioavailability.
Metabolism
Catabolized in a manner similar to endogenous fibrinogen.
Side Effects
Contraindications
- •Hypersensitivity to the active substance, human blood products, or any of the excipients.
- •Known history of severe allergic reactions to any component of the preparation.
Drug Interactions
Other blood products
No specific interactions, but ensure compatibility if mixed.
Heparin and other anticoagulants
May interfere with the effect of fibrinogen and require careful monitoring of coagulation parameters.
Antifibrinolytics (e.g., tranexamic acid, epsilon-aminocaproic acid)
Concomitant administration may increase the risk of thrombotic events. Use with caution.
Storage
Store the unopened vial at room temperature (not exceeding 25°C). Do not freeze. Protect from light. Keep out of reach of children. Do not use if the solution is cloudy or contains particles after reconstitution.
Overdose
Overdose may lead to an increased risk of thrombotic events. In case of overdose, discontinue administration immediately and manage symptomatically, focusing on anticoagulant therapy if thrombosis is suspected.
Pregnancy & Lactation
Use only if clearly indicated and the potential benefits outweigh the potential risks to the fetus or infant. Consult a physician. Data on human pregnancy and lactation are limited.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years when stored as recommended. After reconstitution, the solution should be used immediately, or within 8 hours if stored at room temperature (20-25°C).
Availability
Hospitals, Clinics, Specialized Pharmacies
Approval Status
Approved
Patent Status
Off-patent
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
